NeoGenomics, Inc. (NEO) vs TransMedics Group, Inc. (TMDX)

A side-by-side comparison of NeoGenomics, Inc. and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — NEO vs TMDX

growth of $100 · dividends reinvested · last 7y
NEO -12.5% (-1.9%/yr)TMDX +251.7% (+19.7%/yr)TMDX compounded faster over this window
0200400600800Start $100202120232025$88$352
NEO TMDX

NEO vs TMDX: by the numbers

  • •TMDX is the larger company ($2.76B vs $475M market cap).
  • •TMDX is profitable (22.69% net margin) while NEO runs a net loss (-6.77%).
  • •TMDX grew revenue faster over the past five years (86.12% vs 9.41% CAGR).

Metrics side by side

Valuation

MetricNEOTMDX
P/E ratioN/A20.67
Forward P/E101.0854.40
P/S ratio0.624.13
P/B ratio0.605.32
EV / EBITDAN/A26.71
FCF yieldN/A2.87%

Profitability

MetricNEOTMDX
Gross margin42.92%58.69%
Operating margin-8.63%12.21%
Net margin-6.77%22.69%
ROE-6.60%29.28%
ROIC-5.29%5.87%

Growth (annualized)

MetricNEOTMDX
Revenue CAGR (5Y)9.41%86.12%
Total return CAGR (5Y)-18.18%19.20%

Frequently asked

Which has grown faster, NEO or TMDX?
Over the past five years, TMDX grew revenue faster — NEO at a 9.41% CAGR versus TMDX at 86.12%.
Is NEO or TMDX more profitable?
TMDX runs the higher net margin — NEO at -6.77% versus TMDX at 22.69%.
How have NEO and TMDX total returns compared?
Over the past 5 years, NEO delivered -18.18% and TMDX delivered 19.20% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.